In a remarkable turn of events, pharma giant Novo Nordisk has seen its market value soar to approximately $506 billion, largely attributed to the unprecedented success of its semaglutide-based injectable drugs, Ozempic and Wegovy. The surge in valuation has outpaced the estimated worth of OpenAI, the artificial intelligence (AI) company, by a staggering fivefold. Semaglutide’s
